Zhou S Z, Broxmeyer H E, Cooper S, Harrington M A, Srivastava A
Department of Medicine, Walther Oncology Center, Indiana University School of Medicine, Indianapolis 46202-5120.
Exp Hematol. 1993 Jul;21(7):928-33.
Recombinant human adeno-associated virus 2 (AAV) virions were constructed containing a gene for resistance to neomycin (neoR), under the control of either the herpesvirus thymidine kinase (TK) promoter (vTK-Neo), the murine colony-stimulating factor-1 (CSF-1) promoter (vCSF1-Neo) or the CSF-1 promoter plus an upstream human erythroid cell-specific enhancer, HS-2 (vHS2-CSF1-Neo). Recombinant virions were used to infect low-density murine primary bone marrow cells. In hematopoietic progenitor cell assays initiated with cells infected with these recombinant virions, myeloid as well as erythroid cell colonies resistant to the drug G418, a neomycin analogue, were readily obtained, indicating that the murine hematopoietic progenitor cells were susceptible to infection by the recombinant AAV virions and that the transduced neo gene was functionally active in these cells. Whereas only approximately 10% of the colony-forming unit-granulocyte/macrophage (CFU-GM) colonies cloned from mock-infected cells survived the G418-selection at a final active concentration of 250 micrograms/mL of the drug, the extent of the CFU-GM colony formation initiated with the recombinant AAV-Neo virions was as follows: 15% with vTK-Neo, 22% with vCSF1-Neo and 49% with vHS2-CSF1-Neo. In addition, only 14% of the burst-forming unit-erythroid (BFU-E) colonies from mock-infected cells were resistant to G418, whereas 82% of the BFU-E colonies initiated with cells infected with vHS2-CSF1-Neo virions survived the drug selection, suggesting that a human erythroid cell-specific enhancer was able to potentiate expression of the transduced neoR gene from a murine promoter. Individual CFU-GM and BFU-E colonies from mock-infected or recombinant AAV-Neo virus-infected cultures were subjected to polymerase chain reaction (PCR) analysis using a neo-specific synthetic oligonucleotide primer-pair. A 276 bp DNA fragment that hybridized with a neo-specific DNA probe on Southern blots was detected only in colonies cloned from the recombinant virus-infected cells, indicating stable integration of the transduced neo gene. These studies suggest the feasibility of using the AAV-based vector system in an animal model as a prelude to evaluating its safety and efficacy in human gene therapy.
构建了重组人腺相关病毒2(AAV)病毒粒子,其包含在疱疹病毒胸苷激酶(TK)启动子(vTK-Neo)、鼠集落刺激因子-1(CSF-1)启动子(vCSF1-Neo)或CSF-1启动子加上上游人红细胞特异性增强子HS-2(vHS2-CSF1-Neo)控制下的新霉素抗性基因(neoR)。重组病毒粒子用于感染低密度的鼠原代骨髓细胞。在用这些重组病毒粒子感染的细胞启动的造血祖细胞测定中,很容易获得对新霉素类似物药物G418有抗性的髓系和红系细胞集落,这表明鼠造血祖细胞易受重组AAV病毒粒子感染,并且转导的neo基因在这些细胞中具有功能活性。从模拟感染细胞克隆的集落形成单位-粒细胞/巨噬细胞(CFU-GM)集落中,只有约10%在最终活性浓度为250微克/毫升的G418选择下存活,而用重组AAV-Neo病毒粒子启动的CFU-GM集落形成程度如下:vTK-Neo为15%,vCSF1-Neo为22%,vHS2-CSF1-Neo为49%。此外,模拟感染细胞的爆式红系集落形成单位(BFU-E)集落中只有14%对G418有抗性,而用vHS2-CSF1-Neo病毒粒子感染的细胞启动的BFU-E集落中有82%在药物选择中存活,这表明人红细胞特异性增强子能够增强来自鼠启动子的转导neoR基因的表达。使用neo特异性合成寡核苷酸引物对,对模拟感染或重组AAV-Neo病毒感染培养物中的单个CFU-GM和BFU-E集落进行聚合酶链反应(PCR)分析。仅在从重组病毒感染细胞克隆的集落中检测到与Southern印迹上的neo特异性DNA探针杂交的276 bp DNA片段,表明转导的neo基因稳定整合。这些研究表明,在动物模型中使用基于AAV的载体系统作为评估其在人类基因治疗中的安全性和有效性的前奏是可行的。